Intravacc B.V.
CAGE Code: H2MN6
NCAGE Code: H2MN6
Status: Active
Type: Manufacturer
Summary
Intravacc B.V. is an Active Manufacturer with the Cage Code H2MN6.
Address
Antonie V Leeuwenhoekln 9
Bilthoven
3721 MA
Netherlands
Points of Contact
No Points of Contact...
Related Information
No Related Information...
Frequently Asked Questions (FAQ) for CAGE H2MN6
- What is CAGE Code H2MN6?
- H2MN6 is the unique identifier used by NATO Organizations to reference the physical entity known as Intravacc B.V. located at Antonie V Leeuwenhoekln 9, Bilthoven, 3721 MA, Netherlands.
- Who is CAGE Code H2MN6?
- H2MN6 refers to Intravacc B.V. located at Antonie V Leeuwenhoekln 9, Bilthoven, 3721 MA, Netherlands.
- Where is CAGE Code H2MN6 Located?
- CAGE Code H2MN6 is located in Bilthoven, Netherlands.
Contracting History for CAGE H2MN6 Most Recent 25 Records
- 75N93022C00058
- Development Of An Intranasal Vaccine Against Gonorrhea Based On Outer Membrane Vesicles Combined With Sustained-Release Microspheres Containing Recombinant Human Interleukin-12.
- 1 Sep 2023
- Development Of An Intranasal Vaccine Against Gonorrhea Based On Outer Membrane Vesicles Combined With Sustained-Release Microspheres Containing Recombinant Human Interleukin-12.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,764,248.00
- Department Of Health And Human Services (Hhs)
- 75N93022C00058
- Development Of An Intranasal Vaccine Against Gonorrhea Based On Outer Membrane Vesicles Combined With Sustained-Release Microspheres Containing Recombinant Human Interleukin-12.
- 21 Sep 2022
- Development Of An Intranasal Vaccine Against Gonorrhea Based On Outer Membrane Vesicles Combined With Sustained-Release Microspheres Containing Recombinant Human Interleukin-12.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,007,498.00
- Department Of Health And Human Services (Hhs)
- 75N93022C00058
- Development Of An Intranasal Vaccine Against Gonorrhea Based On Outer Membrane Vesicles Combined With Sustained-Release Microspheres Containing Recombinant Human Interleukin-12.
- 13 Jul 2023
- Development Of An Intranasal Vaccine Against Gonorrhea Based On Outer Membrane Vesicles Combined With Sustained-Release Microspheres Containing Recombinant Human Interleukin-12.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,007,498.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00037
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- 29 Dec 2021
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,063,000.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00037
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- 22 Feb 2023
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,063,000.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00037
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- 31 May 2022
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,063,000.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00037
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- 3 Jul 2023
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $9,148,889.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00037
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- 24 Sep 2021
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,063,000.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00037
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- 10 Mar 2023
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,063,000.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00037
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- 7 Dec 2022
- To Develop An Intramuscular Inactivated Whole Virus Vaccine From Early Product Selection Through A Phase I Clinical Trial To Induce Protection Against Ev D68 Induced Afm.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,063,000.00
- Department Of Health And Human Services (Hhs)